ArticleJournal of experimental & clinical cancer research : CR2013
The inhibitory role of Mir-29 in growth of breast cancer cells.
Article in Journal of experimental & clinical cancer research : CR, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 86 citations in OpenAlex.
- Non-coding RNAs as regulators of chromosomal instability in breast cancer.Frontiers in oncology · 2026Review
- Exploring the contrasts: in-depth analysis of human and canine mammary tumors - discoveries at the frontier.Medicine and pharmacy reports · 2024Review
- Circulating miRNAs signature on breast cancer: the MCC-Spain project.European journal of medical research · 2023Article
- Regulation of ERα-dependent breast cancer metastasis by a miR-29a signaling.Journal of experimental & clinical cancer research : CR · 2023Article
- The Role of miR-29s in Human Cancers-An Update.Biomedicines · 2022Review
- Association between extract of Euphorbia szovitsii and expression level of microRNAs in MDA-MB-231 cell line.Molecular biology reports · 2022Article
- Non-Exosomal and Exosome-Derived miRNAs as Promising Biomarkers in Canine Mammary Cancer.Life (Basel, Switzerland) · 2022Review
- Intricate crosstalk between MYB and noncoding RNAs in cancer.Cancer cell international · 2021Review
- Identification of a six-microRNA signature as a potential diagnostic biomarker in breast cancer tissues.Journal of clinical laboratory analysis · 2021Article
- MicroRNA in combination with HER2-targeting drugs reduces breast cancer cell viability in vitro.Scientific reports · 2021Article
- miR-29a is a negative regulator of influenza virus infection through targeting of the frizzled 5 receptor.Archives of virology · 2021Article
- Association between B-Oncology letters · 2021Review
- Spatial transcriptomics inferred from pathology whole-slide images links tumor heterogeneity to survival in breast and lung cancer.Scientific reports · 2020Article
- miR-29 promotes osteosarcoma cell proliferation and migration by targeting PTEN.Oncology letters · 2019Article
- Emerging ways to treat breast cancer: will promises be met?Cellular oncology (Dordrecht, Netherlands) · 2018Review
- Aberrant miRNAs expressed in HER-2 negative breast cancers patient.Journal of experimental & clinical cancer research : CR · 2018Article
- miR-221 stimulates breast cancer cells and cancer-associated fibroblasts (CAFs) through selective interference with the A20/c-Rel/CTGF signaling.Journal of experimental & clinical cancer research : CR · 2018Article
- Knockdown of microRNA-29a regulates the expression of apoptosis-related genes in MCF-7 breast carcinoma cells.Molecular and clinical oncology · 2018Article
- Suppressive role of microRNA-29 in hepatocellular carcinoma via targeting IGF2BP1.International journal of clinical and experimental pathology · 2018Article
- MYBL2 (B-Myb): a central regulator of cell proliferation, cell survival and differentiation involved in tumorigenesis.Cell death & disease · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mir-29 microRNA families are involved in regulation of various types of cancers. Although Mir-29 was shown to play an inhibitory role in tumorigenesis, the role of Mir-29 in breast cancer still remains obscure. In this study, we showed that Mir-29a is the dominant isoform in its family in mammary cells and expression of Mir-29a was down-regulated in different types of breast cancers. Furthermore, over-expression of Mir-29a resulted in significant slower growth of breast cancer cells and caused higher percentage of cells at G0/G1 phase. Consistent with this over-expression data, knockdown of Mir-29a in normal mammary cells lead to higher cell growth rate, and higher percentage of cells entering S phase. We further found that Mir-29a negatively regulated expression of B-Myb, which is a transcription factor associated with tumorigenesis. The protein levels of Cyclin A2 and D1 are consistent with the protein level of B-Myb. Taken together, our data suggests Mir-29a plays an important role in inhibiting growth of breast cancer cells and arresting cells at G0/G1 phase. Our data also suggests that Mir-29a may suppress tumor growth through down-regulating B-Myb.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.